Alliance for Pandemic Preparedness

June 10, 2021

Immunogenicity of Ad26.COV2.S Vaccine against SARS-CoV-2 Variants in Humans

Category:

Topic:

Keywords (Tags): , ,

  • Median anti-SARS-CoV-2 neutralizing antibody titers of sera from individuals vaccinated with the Johnson & Johnson-Janssen vaccine in the phase 1/2 trials (n=20) were 5- and 3-fold lower against the B.1.351 (Beta) and P.1 (Gamma) variants, respectively, compared with the wild-type strain on day 71 following vaccination. Binding antibody titers were impaired but to a lesser extent, with a 3-fold reduction against both variants compared to the wild-type strain. By contrast, functional non-neutralizing antibody responses and T-cell responses were largely preserved against the variants.

Alter et al. (June 9, 2021). Immunogenicity of Ad26.COV2.S Vaccine against SARS-CoV-2 Variants in Humans. Nature. https://doi.org/10.1038/s41586-021-03681-2